Agoura Hills, United States
A2 Biotherapeutics, Inc. is a biotechnology startup that aims to revolutionize cancer treatment with its powerful and precise T cell therapy. The company's slogan, "Powerful & precise T cell therapy that attacks solid tumors while sparing normal cells," encapsulates its mission to push the boundaries of science and transform medicine.
Founded in 2018 by Alexander Kamb, Michael Gallo, and Paul Kang, A2 is at the forefront of cell therapy, particularly focused on solid tumors. The company engineers T cells to target the loss of genetic material in tumors, enabling the selective killing of tumor cells while sparing normal cells from harm.
A2 has garnered significant interest from investors, raising an impressive $136M since its inception. Notable investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents), and Hartford HealthCare Endowment.
Notably, the company secured a $62.00M Series B investment on 19 December 2022, indicating continued support and confidence from the investment community.
Based in the United States, A2 Biotherapeutics, Inc. represents a promising player in the biotechnology and healthcare industries, with its innovative approach to tackling cancer.
Tmunity Therapeutics
